{"title":"Prediction and Monitoring of Adaptive Radiation Therapy Timing Using Two-dimensional X-ray Image-based Water Equivalent Thickness.","authors":"Kouta Hirotaki, Shunsuke Moriya, Kento Tomizawa, Masashi Wakabayashi, Atsushi Motegi, Masashi Ito, Takeji Sakae","doi":"10.21873/anticanres.17427","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to predict the optimal timing for adaptive radiation therapy (ART) using two-dimensional X-ray image-based water equivalent thickness (2DWET).</p><p><strong>Patients and methods: </strong>Forty patients with oropharyngeal and hypopharyngeal cancer underwent Computed Tomography (CT) rescanning during treatment. An adaptive score (AS) was proposed to guide ART decisions based on changes in four dose indices: target coverage, spinal cord dose, parotid gland dose, and over-dose volume. Delivered dose distributions were reviewed by two head and neck radiation oncologists, with ART requirement evaluated using a four-point scale. Logistic regression determined the AS cutoff, while receiver operating characteristic analysis assessed 2DWET as a predictor of ART timing.</p><p><strong>Results: </strong>The AS strongly correlated with the oncologists' ART decisions (Pearson coefficients of 0.74 and 0.64). An AS cutoff of 7.5 optimally indicated ART requirement, matching oncologist decisions with sensitivities of 79.2% and 89.5%, and specificities of 87.5% and 81.0%, respectively. The 2DWET method identified the AS threshold of 7.5 with sensitivity and specificity of 63.2% and 81.0%.</p><p><strong>Conclusion: </strong>An AS of 7.5 was highly indicative of ART timing, aligning well with oncologists' decisions, and 2DWET demonstrated potential as a low-exposure, efficient tool for predicting ART timing in patients with oropharyngeal and hypopharyngeal cancers.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"387-397"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17427","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: This study aimed to predict the optimal timing for adaptive radiation therapy (ART) using two-dimensional X-ray image-based water equivalent thickness (2DWET).
Patients and methods: Forty patients with oropharyngeal and hypopharyngeal cancer underwent Computed Tomography (CT) rescanning during treatment. An adaptive score (AS) was proposed to guide ART decisions based on changes in four dose indices: target coverage, spinal cord dose, parotid gland dose, and over-dose volume. Delivered dose distributions were reviewed by two head and neck radiation oncologists, with ART requirement evaluated using a four-point scale. Logistic regression determined the AS cutoff, while receiver operating characteristic analysis assessed 2DWET as a predictor of ART timing.
Results: The AS strongly correlated with the oncologists' ART decisions (Pearson coefficients of 0.74 and 0.64). An AS cutoff of 7.5 optimally indicated ART requirement, matching oncologist decisions with sensitivities of 79.2% and 89.5%, and specificities of 87.5% and 81.0%, respectively. The 2DWET method identified the AS threshold of 7.5 with sensitivity and specificity of 63.2% and 81.0%.
Conclusion: An AS of 7.5 was highly indicative of ART timing, aligning well with oncologists' decisions, and 2DWET demonstrated potential as a low-exposure, efficient tool for predicting ART timing in patients with oropharyngeal and hypopharyngeal cancers.
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.